Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Immunic CEO Daniel Vitt discusses rise in autoimmune diseases and MS treatments
MP3•Episode home
Manage episode 425510984 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Immunic Inc CEO Daniel Vitt speaks to Proactive's Stephen Gunnion about the rise of autoimmune diseases such as multiple sclerosis (MS) and celiac disease, attributing this trend to environmental and diagnostic factors. Vitt highlighted how better diagnostic tools have identified more cases, previously undetected. Vitt discussed Immunic’s lead asset for treating MS, emphasizing the urgent need for treatments addressing disability worsening, which current drugs do not fully cover. He explained the unique attributes of the oral small molecule vidofludimus calcium, developed by Immunic, which has a triple activity - anti-inflammatory, antiviral, and neuroprotective properties. This combination could address the unmet need in MS treatments, particularly in non-relapsing patients. Vitt also updated on the recruitment progress for Immunic's phase 3 trials in relapsing MS, stating the trials are on schedule. He expressed optimism about the potential of their phase 2 results in progressive MS expected in April 2025, describing it as a possible game-changer. Visit Proactive's YouTube channel for more insightful interviews. Don’t forget to like this video, subscribe to our channel, and enable notifications for future content. #ImmunicInc #AutoimmuneDiseases #MultipleSclerosis #MSResearch #VidofludimusCalcium #Biotech #HealthcareInnovation #ClinicalTrials #Neuroprotection #ProactiveInterviews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodes
MP3•Episode home
Manage episode 425510984 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Immunic Inc CEO Daniel Vitt speaks to Proactive's Stephen Gunnion about the rise of autoimmune diseases such as multiple sclerosis (MS) and celiac disease, attributing this trend to environmental and diagnostic factors. Vitt highlighted how better diagnostic tools have identified more cases, previously undetected. Vitt discussed Immunic’s lead asset for treating MS, emphasizing the urgent need for treatments addressing disability worsening, which current drugs do not fully cover. He explained the unique attributes of the oral small molecule vidofludimus calcium, developed by Immunic, which has a triple activity - anti-inflammatory, antiviral, and neuroprotective properties. This combination could address the unmet need in MS treatments, particularly in non-relapsing patients. Vitt also updated on the recruitment progress for Immunic's phase 3 trials in relapsing MS, stating the trials are on schedule. He expressed optimism about the potential of their phase 2 results in progressive MS expected in April 2025, describing it as a possible game-changer. Visit Proactive's YouTube channel for more insightful interviews. Don’t forget to like this video, subscribe to our channel, and enable notifications for future content. #ImmunicInc #AutoimmuneDiseases #MultipleSclerosis #MSResearch #VidofludimusCalcium #Biotech #HealthcareInnovation #ClinicalTrials #Neuroprotection #ProactiveInterviews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.